文献速递临床免疫临床血液与体液

新型即时TAT免疫检测及联合血栓标志物组合用于结直肠癌VTE风险分层的多中心临床验证

Multicenter clinical validation of a novel rapid single-integrated TAT immunoassay and combined thrombosis biomarker panel for venous thromboembolism risk stratification in colorectal cancer.
PubMed 文献 · Clin Chim Acta · 2025-09-29

本研究验证新型即时检测技术测量凝血酶-抗凝血酶III复合物(TAT)的可靠性,并评估其在结直肠癌(CRC)患者静脉血栓栓塞症(VTE)风险分层和动态监测中的价值。新型TAT检测与参考方法相关性极佳(r > 0.99),CRC患者TAT、PIC、TM、tPAIC均显著升高(p < 0.001),TAT和联合模型对VTE预测的AUC为0.9544,灵敏度90.5%,特异度93.5%。

要点

  • 新型即时TAT检测与参考方法相关性极佳(r > 0.99),可用于临床。
  • CRC患者TAT和PIC分别升高3.5倍和2.4倍,晚期患者TAT中位数高1.8倍。
  • TAT联合标志物模型预测VTE的AUC为0.9544,灵敏度90.5%,特异度93.5%。

核心结论

  • 新型TAT即时免疫检测是可靠的临床检测系统。
  • 联合生物标志物模型可增强CRC患者VTE风险分层,为个体化抗凝治疗和动态监测提供策略。

研究设计与样本

  • 多中心临床验证研究,评估新型即时TAT免疫检测与参考系统的相关性。
  • 在CRC患者和健康对照中定量检测TAT、PIC、TM和tPAIC。
  • 采用ROC曲线分析评估标志物对VTE风险分层的预测性能。

主要发现

  • 新型TAT检测与参考方法相关性极佳(r > 0.99)。
  • CRC患者所有标志物较健康对照显著升高(p < 0.001),TAT和PIC分别升高3.5倍和2.4倍。
  • CRC伴VTE与不伴VTE患者间TAT、PIC和tPAIC水平差异显著(p < 0.001)。
  • 晚期患者TAT中位浓度较早期患者高1.8倍(p < 0.001)。
  • ROC分析显示TAT和联合标志物模型预测性能强,AUC为0.9544,灵敏度90.5%,特异度93.5%。

关键数值与推荐

  • 新型TAT检测与参考方法相关系数r > 0.99。
  • CRC患者较健康对照TAT升高3.5倍、PIC升高2.4倍(p < 0.001)。
  • 晚期较早期CRC患者TAT中位浓度高1.8倍(p < 0.001)。
  • TAT和联合模型预测VTE的AUC为0.9544,灵敏度90.5%,特异度93.5%。

临床怎么用

  • 可采用新型即时TAT免疫检测进行临床TAT测量。
  • 联合TAT、PIC、TM和tPAIC标志物模型可用于CRC患者VTE风险分层。
  • 该策略有助于个体化抗凝治疗和动态监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to validate the reliability of a novel point-of-care testing technology for measuring the thrombin-antithrombin III complex (TAT) and to evaluate its utility in evaluating venous thromboembolism (VTE) risk and enabling dynamic monitoring in patients with colorectal cancer (CRC). DESIGN AND METHODS: The novel immunoassay for TAT measurement was assessed against a reference system. Biomarker levels-including TAT, plasmin-α2-antiplasmin complex (PIC), thrombomodulin (TM), and tissue plasminogen activator-inhibitor complex (tPAIC)-were quantified in patients with CRC and healthy controls. Statistical analyses were conducted to assess differences among various groups. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the predictive performance of biomarkers for VTE risk stratification. RESULTS: The novel TAT assay showed excellent correlation with the reference method (r > 0.99). All biomarkers were significantly elevated in CRC patients compared to healthy controls (p < 0.001), with TAT and PIC levels increasing by 3.5-fold and 2.4-fold, respectively. Significant differences in the levels of TAT, PIC, and tPAIC were also observed between CRC patients with VTE and those without VTE (p < 0.001). Advanced-stage patients showed a median TAT concentration 1.8-fold higher than early-stage patients (p < 0.001). ROC analysis revealed strong predictive performance for TAT and the combined biomarker model, with an area under the curve (AUC) of 0.9544, sensitivity of 90.5 %, and specificity of 93.5 %. CONCLUSIONS: The novel TAT immunoassay represents a reliable system for clinical application. Furthermore, a combined biomarker model enhances VTE risk stratification in CRC patients, providing a valuable strategy for personalized anticoagulant therapy and dynamic monitoring.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Liu M, Guo C, Zhou H, et al. Multicenter clinical validation of a novel rapid single-integrated TAT immunoassay and combined thrombosis biomarker panel for venous thromboembolism risk stratification in colorectal cancer. Clin Chim Acta. 2025. PMID: 41033426. doi:10.1016/j.cca.2025.120631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。